Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Q2 Revenues Jump 24 Percent

NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Monday that its second quarter revenues rose 24 percent year over year as it beat analysts' consensus estimates on both the top and bottom lines.

For the three months ended June 30, the South San Francisco, California-based molecular diagnostics firm reported total revenues of $22.8 million, compared to $18.4 million a year ago. On average, analysts had expected Q2 revenues of $20.6 million.

The company reported genomic test volume of 7,686 tests in Q2, up 18 percent from the same quarter last year. Veracyte said that it tripled revenues from its Percepta bronchial genomic classifier compared to the first quarter, and that the number of physicians ordering the test grew by 50 percent sequentially.

During Q2 Veracyte also received regulatory approval from the New York State Department of Health, enabling it to move all of its Afirma thyroid cancer diagnostic tests to the genomic sequencing classifier. The company also commercially launched the Afirma Xpression Atlas, which uses RNA sequencing to inform surgery and treatment decisions in patients with suspected thyroid cancer.

Veracyte's Q2 net loss narrowed to $6.2 million, or $.18 per share, from $7.3 million, or $.22 per share in the year-ago period, beating Wall Street's estimate for a loss per share of $.27.

The firm's R&D expenses in Q2 were $4.6 million, up 28 percent from $3.6 million a year ago, while its SG&A expenses climbed 10 percent to $15.6 million from $14.2 million.

Veracyte finished Q2 with $23.8 million in cash and cash equivalents.

The strong quarter prompted Veracyte to raise its 2018 annual revenue guidance to between $87 million and $89 million from a previously updated guidance of $83 million to $86 million. Analysts are expecting 2018 revenues of $84.5 million.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.